Advertisement
Screener

Elite Pharmaceuticals, Inc. (ELTP) Revenues

2.8 / 5 stars · 68/120 Roast Me

Elite Pharmaceuticals, Inc. Revenues

Elite Pharmaceuticals, Inc. (ELTP) reported Revenues of $25.38 million for the 12-month period ending 2021-03-31, per its 10-K filed 2021-06-14.

Discontinued › Income Statement › Revenue

us-gaap:Revenues · last filed 2021-06-14

  • Elite Pharmaceuticals, Inc. revenues for the quarter ending 2021-03-31 was $4.40M, a 11.12% decline year-over-year.
  • Elite Pharmaceuticals, Inc. revenues for the quarter ending 2020-12-31 was $6.05M, a 19.61% increase year-over-year.
  • Elite Pharmaceuticals, Inc. revenues for the quarter ending 2020-09-30 was $7.40M, a 59.65% increase year-over-year.
  • Elite Pharmaceuticals, Inc. revenues for the quarter ending 2020-06-30 was $7.54M, a 124.42% increase year-over-year.
  • Elite Pharmaceuticals, Inc. revenues for fiscal 2021 was $25.38M, a 41.05% increase from fiscal 2020.
  • Elite Pharmaceuticals, Inc. revenues for fiscal 2020 was $17.99M, a 137.76% increase from fiscal 2019.
  • Elite Pharmaceuticals, Inc. revenues for fiscal 2019 was $7.57M, a 1.47% increase from fiscal 2018.
  • Elite Pharmaceuticals, Inc. revenues for fiscal 2018 was $7.46M.
Period endRevenues 3 monthRevenues 6 monthRevenues 9 monthRevenues 12 month
2021-03-31$4.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-06-14
$10.44M
derived: sum of 2 quarters · filed 2021-06-14
$17.84M
derived: sum of 3 quarters · filed 2021-06-14
$25.38M
10-K · filed 2021-06-14
2020-12-31$6.05M
10-Q · filed 2021-02-16
$13.45M
derived: sum of 2 quarters · filed 2021-02-16
$20.99M
10-Q · filed 2021-02-16
$25.93M
derived: sum of 4 quarters · filed 2021-06-14
2020-09-30$7.40M
10-Q · filed 2020-11-16
$14.94M
10-Q · filed 2020-11-16
$19.88M
derived: sum of 3 quarters · filed 2021-06-14
$24.94M
derived: sum of 4 quarters · filed 2021-06-14
2020-06-30$7.54M
10-Q · filed 2020-08-14
$12.48M
derived: sum of 2 quarters · filed 2021-06-14
$17.54M
derived: sum of 3 quarters · filed 2021-06-14
$22.17M
derived: sum of 4 quarters · filed 2021-06-14
2020-03-31$4.95M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-06-14
$10.00M
derived: sum of 2 quarters · filed 2021-06-14
$14.64M
derived: sum of 3 quarters · filed 2021-06-14
$17.99M
10-K · filed 2021-06-14
2019-12-31$5.06M
10-Q · filed 2021-02-16
$9.69M
derived: sum of 2 quarters · filed 2021-02-16
$13.05M
10-Q · filed 2021-02-16
$14.39M
derived: sum of 4 quarters · filed 2021-02-16
2019-09-30$4.63M
10-Q · filed 2020-11-16
$7.99M
10-Q · filed 2020-11-16
$9.34M
derived: sum of 3 quarters · filed 2020-11-16
$12.03M
derived: sum of 4 quarters · filed 2020-11-16
2019-06-30$3.36M
10-Q · filed 2020-08-14
$4.70M
derived: sum of 2 quarters · filed 2020-08-14
$7.40M
derived: sum of 3 quarters · filed 2020-08-14
$8.76M
derived: sum of 4 quarters · filed 2020-08-14
2019-03-31$1.34M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-29
$4.04M
derived: sum of 2 quarters · filed 2020-06-29
$5.40M
derived: sum of 3 quarters · filed 2020-06-29
$7.57M
10-K · filed 2020-06-29
2018-12-31$2.69M
10-Q · filed 2020-02-10
$4.06M
derived: sum of 2 quarters · filed 2020-02-10
$6.22M
10-Q · filed 2020-02-10
$7.82M
derived: sum of 4 quarters · filed 2020-02-10
2018-09-30$1.36M
10-Q · filed 2019-11-12
$3.53M
10-Q · filed 2019-11-12
$5.13M
derived: sum of 3 quarters · filed 2019-11-12
$7.66M
derived: sum of 4 quarters · filed 2019-11-12
2018-06-30$2.17M
10-Q · filed 2019-08-09
$3.76M
derived: sum of 2 quarters · filed 2019-08-09
$6.30M
derived: sum of 3 quarters · filed 2019-08-09
$7.92M
derived: sum of 4 quarters · filed 2019-08-09
2018-03-31$1.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-06-21
$4.13M
derived: sum of 2 quarters · filed 2019-06-21
$5.76M
derived: sum of 3 quarters · filed 2019-06-21
$7.46M
10-K · filed 2019-06-21
2017-12-31$2.54M
10-Q · filed 2019-02-11
$4.16M
derived: sum of 2 quarters · filed 2019-02-11
$5.86M
10-Q · filed 2019-02-11
2017-09-30$1.62M
10-Q · filed 2018-11-09
$3.33M
10-Q · filed 2018-11-09
2017-06-30$1.70M
10-Q · filed 2018-08-09